Predictors of subsequent myocardial infarction, stroke, and death in stable post-myocardial infarction patients: A nationwide cohort study

Chen, Dong‐Yi; Li, Chenyu; Hsieh, Ming‐Jer; Chen, Chun‐Chi; Chen, Tien-Hsing; Chen, Shaowei; Wang, Chao-Yung; Chang, Shang‐Hung; Lee, Cheng-Hung; Tsai, Ming-Lung; Ho, Ming-Yun; Yeh, Jiun‐Ting; Chang, Chee‐Jen; Wen, Ming‐Shien

doi:10.1177/2048872617730037

Cited by 14 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may have further shortened the mean follow‐up period in this study. Despite the higher rate of early discontinuation of DAPT, the risk of death, MI, and stroke at 1 year after AMI was not higher in a Taiwan nationwide cohort study than in a Swedish national registry study (15.1% vs. 18.3%) 37,38 . Pivotal trials of ticagrelor and prasugrel in ACS have shown greatest ischemic reduction during the first month following the treatment initiation 9,39 .…”

Section: Discussionmentioning

confidence: 95%

Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study

Chang

Tung

Liu

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Ticagrelor improves clinical outcomes in patients with acute myocardial infarction (AMI). This study aimed to compare the efficacy and safety of ticagrelor vs. clopidogrel in East Asian patients with AMI. Between July 2013 and December 2015, patients with AMI prescribed dual antiplatelet therapy were identified from the National Health Insurance Research Database of Taiwan. Using propensity score weighting, ticagrelor was compared with clopidogrel for the primary efficacy end point (a composite of all‐cause death, myocardial infarction (MI), and stroke) and bleeding. A total of 32,442 patients with AMI (ticagrelor: 10,057; clopidogrel: 22,385) were eligible for analysis. After propensity score weighting, ticagrelor was comparable to clopidogrel in the incidence rate of the primary efficacy end point (23.6 vs. 22.76/100 patient‐years; hazard ratio (HR) 0.97; 95% confidence interval (CI) 0.89–1.06; P = 0.513). Ticagrelor was associated with a lower risk of stroke (1.78 vs. 2.66/100 patient‐years; HR 0.64; 95% CI 0.49–0.85; P = 0.002) and higher risks of overall (21.59 vs. 18.35/100 patient‐years; HR 1.16; 95% CI 1.06–1.27; P = 0.002) and Bleeding Academic Research Consortium (BARC) type 2 bleeding (18.67 vs. 15.08/100 patient‐years; HR 1.22; 95% CI 1.11–1.36; P < 0.001). The risks of death, MI, and BARC 3 or 5 bleeding were comparable between ticagrelor and clopidogrel. In the present study, ticagrelor was comparable to clopidogrel in the composite of death, MI, and stroke, but had an increased risk of BARC type 2 bleeding. Ticagrelor may be beneficial in preventing post‐MI stroke in East Asian patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study

Chang

Tung

Liu

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Independent predictors of recurrent CVD events or death include age, smoking, hypertension (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines [9, 10]. A previous study conducted in the United Arab Emirates (UAE) reported 35% with HTN, 34% having dyslipidemia, 14.4% had a history of coronary artery disease (CAD) and 29.5% with diabetes mellitus also had concomitant macrovascular complications [11].…”

Section: Introductionmentioning

confidence: 99%

Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study

Govender

Al-Shamsi

Soteriades

et al. 2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundIndividuals with established cardiovascular disease (CVD) and risk factors such as age, smoking, hypertension, and diabetes mellitus are at an increased risk of recurrent cardiovascular events and death. The incidence rate of recurrent CVD events varies between countries and populations. The United Arab Emirates (UAE) has one of the highest age-standardized death rates for CVD worldwide. The aim of our study was to estimate the incidence rates and determine the predictors of recurrent CVD events among UAE nationals.MethodsWe investigated an outpatient-based cohort of patients with a history of CVD visiting Tawam Hospital between April 1, 2008 and December 31, 2008. They were followed-up until July 31, 2018. Univariable and multivariable Cox proportional hazards regression models were used to determine the association between major CVD risk factors and the risk of CVD recurrence.ResultsA total of 216 patients (167 males, 49 females) with a history of CVD were included. They were followed for a median (interquartile range) of 8.1 (5.5–9.3) years, with a total of 1184 patient-years of follow-up. The overall incidence rate of recurrent CVD events was 92.1 per 1000 patient-years. The 8-year cumulative incidence was 73.7%. Age, female sex, and diabetes mellitus were significant predictors of recurrent CVD events, where females had a 1.96 times higher risk of recurrent CVD events than males.ConclusionSignificant predictors of recurrent CVD events are older age, female sex, and diabetes mellitus. The incidence rate of recurrent CVD events was 92.1 per 1000 patient-years. Preventive measures, based on international guidelines for CVD management, may improve CVD morbidity and mortality in the UAE population.

show abstract

“…A meta-analysis by Lewington et al links arterial hypertension to death from myocardial infarction as well as stroke in middle and old age. 55 Chen et al found arterial hypertension to be an independent risk factor for death from myocardial infarction, hypertension and prior stroke in survivors of previous myocardial infarction, 56 and Thune et al found that antecedent hypertension independently increased the risk of heart failure. 57 …”

Section: The Basis Of Chiropractic To Cardiovascular Physiologymentioning

confidence: 99%

The Kaleidoscope Model of Integrative Healthcare as a collaborative paradigm for cardiology and chiropractic: a call to action

Cohen¹,

Schulman

Masarsky

et al. 2018

Integrative Medicine Research

View full text Add to dashboard Cite

This review article proposes a model of integrative care for cardiovascular patients in institutional settings. We review relevant historic and contemporary examples of medical–chiropractic cooperation and a brief review of the literature illustrating the clinical benefits of chiropractic care for patients with cardiovascular disease. The groundwork proposes a distinct research and clinical practice model incorporating the doctor of chiropractic (D.C.) as a synergistic partner with the medical cardiologist coined the Kaleidoscope Model of Integrative Care (KM). While a traditional kaleidoscope does not alter the nature of light itself, the observer does see the ‘raw data’ of colors and shapes, wavelengths, etc. contained within the “potential” of the light itself; left unrecognized, even subtle re-orientations of the instrument changes the perspective. Similarly, the KM is intended as a conduit for slight reorientations to traditional medical–chiropractic–patient hierarchies, thus creating new treatment options and generating robust changes in inter-professional perception of the patient's condition(s) and treatment options. It is hoped that this model will not only serve future patients within hospitals, but that institutions will serve as incubators for better collaboration and research among the majority of free-standing medical and chiropractic practices ultimately benefitting the patient with cardiovascular disease.

show abstract

Predictors of subsequent myocardial infarction, stroke, and death in stable post-myocardial infarction patients: A nationwide cohort study

Cited by 14 publications

References 25 publications

Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study

Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study

Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study

The Kaleidoscope Model of Integrative Healthcare as a collaborative paradigm for cardiology and chiropractic: a call to action

Contact Info

Product

Resources

About